Mason Capital Management LLC’s Kenneth M Garschina said he wants Grifols SA’s board replaced. The co-founder of the New ...

The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance about €1.4 billion ($1.48 billion) in bonds ...

For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

Canadian fund Brookfield said on Wednesday it has dropped its plan to take over Spain's Grifols due to a disagreement over ...

Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ: GRFS) class A ...

Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

JPMorgan lowered the firm’s price target on Grifols (GRFS) to EUR 9.50 from EUR 14 and keeps a Neutral rating on the shares. Don't Miss our Black Friday Offers: Published first on TheFly – the ...

Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the "Clients") holding in aggregate 5.65% of A shares and 3.88% of B shares (including ADRs) in ...

On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a ...

With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...

Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...